The novelty of our work that we show the more comprehensive effects of PROTACs to BTK on proximal and downstream BCR signaling, activation, migration and apoptosis in patients derived CLL cells including those with different BTK mutations at C481. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.